Showing 3921-3930 of 10490 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0309_06-php/22860/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0209_05-php/22877/Noah Worcester 2024: Dr. Green and Dr. Weinstein on Medicare
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-green-and-dr-weinstein-medicare/24582/Noah Worcester 2024: Dr. Green and Dr. Weinstein on MedicareYour Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/20669/Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/20847/Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/general-topics/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/21061/An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.DermWireTV Update
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-update/19125/Allergan is business as usual following a revised merger offer from Valeant. Get an update on the offer and Allergan's recent nominationfor the Prixe Galien USA.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.